TENET HEALTHCARE CORP

For the period ended Dec 31, 2025. Filed Feb 17, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 17, 2026

THC$289.00+2.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		TENET HEALTHCARE CORPORATION(Registrant)
Date: February 17, 2026	By:	/s/ R. SCOTT RAMSEY
		R. Scott RamseySenior Vice President, Controller (Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Date: February 17, 2026	By:	/s/ SAUMYA SUTARIA
		Saumya Sutaria, M.D.Chairman of the Board and Chief Executive Officer(Principal Executive Officer)
Date: February 17, 2026	By:	/s/ SUN PARK
		Sun ParkExecutive Vice President and Chief Financial Officer(Principal Financial Officer)
Date: February 17, 2026	By:	/s/ R. SCOTT RAMSEY
		R. Scott RamseySenior Vice President, Controller(Principal Accounting Officer)
Date: February 17, 2026	By:	/s/ VINEETA AGARWALA
		Vineeta Agarwala, M.D., PhDDirector
Date: February 17, 2026	By:	/s/ JAMES L. BIERMAN
		James L. BiermanDirector
Date: February 17, 2026	By:	/s/ ROY D. BLUNT
		Roy D. BluntDirector
Date: February 17, 2026	By:	/s/ RICHARD FISHER
		Richard FisherDirector
Date: February 17, 2026	By:	/s/ MEGHAN M. FITZGERALD
		Meghan M. FitzGerald, DrPHDirector
Date: February 17, 2026	By:	/s/ CECIL D. HANEY
		Cecil D. HaneyDirector
Date: February 17, 2026	By:	/s/ J. ROBERT KERREY
		J. Robert KerreyDirector
Date: February 17, 2026	By:	/s/ CHRIS LYNCH
		Chris LynchDirector
Date: February 17, 2026	By:	/s/ RICHARD MARK
		Richard MarkDirector

Date: February 17, 2026	By:	/s/ TAMMY ROMO
		Tammy RomoDirector
Date: February 17, 2026	By:	/s/ NADJA WEST
		Nadja West, M.D.Director

SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS

(In Millions)

	Balance atBeginningof Period	Costs andExpenses(1)	Deductions	OtherItems	Balance atEnd ofPeriod
Valuation allowance for deferred tax assets:
Year ended December 31, 2025	$158	$11	$—	$(9)	$160
Year ended December 31, 2024	$248	$(182)	$—	$92	$158
Year ended December 31, 2023	$177	$71	$—	$—	$248

(1)	Includes amounts recorded in discontinued operations.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.